SCHEMBL6542287

SCHEMBL6542287

CNCCCCNc1nc(Nc2ccc(S(N)(=O)=O)cc2)ncc1Br

nearest known ligand 0.69

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CA2 P00918 7/20 0.69
CDK1 P06493 9/20 0.61
KDR P35968 8/20 0.61
CDK2 P24941 8/20 0.61
CDK4 P11802 2/20 0.61
CDK7 P50613 2/20 0.61
CDK9 P50750 2/20 0.61
CCNT1 O60563 1/20 0.61
CCND1 P24385 1/20 0.61
CCNH P51946 1/20 0.61
PTK2 Q05397 3/20 0.60
CCNB1 P14635 2/20 0.60
CCNE1 P24864 2/20 0.60
STK17A Q9UEE5 4/20 0.57
STK17B O94768 1/20 0.57
CA1 P00915 4/20 0.53
CA9 Q16790 4/20 0.53
IGF1R P08069 2/20 0.52
CA12 O43570 2/20 0.51
CDC7 O00311 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3865620 0.90 STK17A (0.68) CA2CDK1KDRCDK2CDK4
SCHEMBL4067086 0.89 CA2 (0.66) CA2CDK1KDRCDK2CDK4
SCHEMBL3873050 0.89 STK17A (0.73) CA2CDK1KDRCDK2CDK4
SCHEMBL4060838 0.88 CA2 (0.62) CA2CDK1KDRCDK2CDK4
SCHEMBL13901432 0.88 CA2 (0.53) CA2CDK1KDRCDK2CDK4
Hydrochloric Acid SCHEMBL3869305 0.88 STK17A (0.71) CA2CDK1KDRCDK2CDK4
SCHEMBL3867378 0.87 CA2 (0.64) CA2CDK1KDRCDK2CDK4
SCHEMBL4058029 0.87 CA2 (0.67) CA2CDK1KDRCDK2CDK4
SCHEMBL6448921 0.86 CA2 (0.65) CA2CDK1KDRCDK2CDK4
SCHEMBL4064853 0.85 CA2 (0.61) CA2CDK1KDRCDK2CDK4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-1717396-A Chk-, Pdk- and Akt-inhibitory pyrimidines, their production and use as pharmaceutical agents SCHERING AG (DE) 2006-01-04 CN claimed
US-20040186118-A1 Chk-, Pdk- and Akt-inhibitory pyrimidines, their production and use as pharmaceutical agents BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) 2004-09-23 US claimed
US-7504410-B2 Chk-, Pdk- and Akt-inhibitory pyrimidines, their production and use as pharmaceutical agents SCHERING AKTIENGESELLSCHAFT (DE) 2009-03-17 US disclosed
CN-1717396-A Chk-, Pdk- and Akt-inhibitory pyrimidines, their production and use as pharmaceutical agents SCHERING AG (DE) 2006-01-04 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040186118-A1 Chk-, Pdk- and Akt-inhibitory pyrimidines, their production and use as pharmaceutical agents DCK, PDPK1, DTYMK CA2 3940/4885CDK1 237/4885KDR 645/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.